Guggenheim Raises Tempus AI (TEM) Price Target, Maintaining Buy Rating

Tempus AI, Inc. (NASDAQ:TEM) is one of the top 10 healthcare AI stocks to buy according to hedge funds.

On June 30, 2025, Guggenheim analyst Subbu Nambi reaffirmed a “Buy” rating on Tempus AI, Inc. (NASDAQ:TEM), while raising the firm’s price target from $65.00 to $75.00. The revised target reflects growing confidence in Tempus’ expanding role in transforming clinical care through precision medicine and data-driven insights.

Guggenheim Raises Tempus AI (TEM) Price Target, Maintaining Buy Rating

A technician in a lab coat working on a specialized multi-axis coating system.

Guggenheim’s updated price target follows steady progress in Tempus’ commercial partnerships and a growing footprint in both academic medicine and biopharmaceutical development. The analyst highlighted the company’s ability to scale its platform across specialties, pointing to its integrated software, sequencing, and analytics solutions as core strengths in a rapidly evolving healthcare landscape. As demand for personalized and evidence-based care accelerates, Tempus AI, Inc. (NASDAQ:TEM) is well-positioned to play a central role in the shift toward smarter, more predictive medicine. Guggenheim’s outlook underscores the firm’s belief that Tempus’ growth trajectory is both sustainable and strategically aligned with the future of healthcare delivery.

Tempus AI operates at the intersection of technology and healthcare, using one of the largest structured clinical and molecular data libraries in the world to personalize treatment decisions. The company works with hospitals, research institutions, and pharmaceutical firms to integrate real-world evidence into patient care, particularly in oncology, cardiology, and infectious diseases. Tempus’ proprietary platform uses machine learning and high-performance computing to uncover patterns in clinical and genomic data, enabling more accurate diagnoses and more effective therapies.

While we acknowledge the potential of TEM to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TEM and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 13 Best Biotech Stocks To Invest In Now and 12 Best Healthcare Stocks to Buy Now.

Disclosure: None.